Loading...

Madrigal Pharmaceuticals

DB:YDO1
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
YDO1
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The last earnings update was 53 days ago. More info.


Add to Portfolio Compare Print
  • Madrigal Pharmaceuticals has significant price volatility in the past 3 months.
YDO1 Share Price and Events
7 Day Returns
-16.3%
DB:YDO1
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-5.8%
DB:YDO1
-10.2%
DE Biotechs
-6%
DE Market
YDO1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Madrigal Pharmaceuticals (YDO1) -16.3% -25.1% -13.4% -5.8% - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • YDO1 outperformed the Biotechs industry which returned -10.2% over the past year.
Price Volatility
YDO1
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Madrigal Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Madrigal Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €90.71.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Madrigal Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Madrigal Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:YDO1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.22
NasdaqCM:MDGL Share Price ** NasdaqCM (2019-04-18) in USD $105.56
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Madrigal Pharmaceuticals.

DB:YDO1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:MDGL Share Price ÷ EPS (both in USD)

= 105.56 ÷ -2.22

-47.6x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Madrigal Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Madrigal Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Madrigal Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:YDO1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -47.6x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
-5.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Madrigal Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Madrigal Pharmaceuticals's assets?
Raw Data
DB:YDO1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $30.95
NasdaqCM:MDGL Share Price * NasdaqCM (2019-04-18) in USD $105.56
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:YDO1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:MDGL Share Price ÷ Book Value per Share (both in USD)

= 105.56 ÷ 30.95

3.41x

* Primary Listing of Madrigal Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Madrigal Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Madrigal Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Madrigal Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Madrigal Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-5.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Madrigal Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Madrigal Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Madrigal Pharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Madrigal Pharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:YDO1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:YDO1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts -5.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:YDO1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:YDO1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 275 -89 -15 6
2022-12-31 83 -137 -103 4
2021-12-31 3 -107 -113 8
2020-12-31 0 -68 -83 9
2019-12-31 0 -50 -62 9
DB:YDO1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -26 -33
2018-09-30 -25 -30
2018-06-30 -25 -30
2018-03-31 -27 -32
2017-12-31 -22 -31
2017-09-30 -22 -30
2017-06-30 -26 -36
2017-03-31 -21 -31
2016-12-31 -18 -26
2016-09-30 -13 -21
2016-06-30 -5 -8
2016-03-31 -3 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Madrigal Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Madrigal Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:YDO1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from Madrigal Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:YDO1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.16 26.27 -6.45 6.00
2022-12-31 -3.81 5.83 -8.38 6.00
2021-12-31 -6.34 -4.11 -8.17 6.00
2020-12-31 -4.97 -4.48 -5.40 6.00
2019-12-31 -3.99 -3.60 -4.44 6.00
DB:YDO1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.22
2018-09-30 -2.11
2018-06-30 -2.22
2018-03-31 -2.46
2017-12-31 -2.54
2017-09-30 -2.54
2017-06-30 -3.25
2017-03-31 -3.76
2016-12-31 -5.07
2016-09-30 -1.77
2016-06-30 -7.48
2016-03-31 -6.49

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Madrigal Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Madrigal Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Madrigal Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Madrigal Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Madrigal Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Madrigal Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Madrigal Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Madrigal Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Madrigal Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Madrigal Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:YDO1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -32.81 15.29 25.39
2018-09-30 -29.78 12.11 23.03
2018-06-30 -29.63 8.94 23.50
2018-03-31 -31.52 7.85 25.21
2017-12-31 -31.15 7.67 24.39
2017-09-30 -30.46 6.91 23.40
2017-06-30 -36.14 9.14 24.53
2017-03-31 -30.67 8.06 19.80
2016-12-31 -26.39 6.59 15.93
2016-09-30 -20.52 5.10 11.18
2016-06-30 -8.27 1.12 4.06
2016-03-31 -7.18 0.83 2.60
2015-12-31 -6.84 0.81 2.43
2014-12-31 -4.49 0.55 0.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Madrigal Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Madrigal Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Madrigal Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Madrigal Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Madrigal Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Madrigal Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Madrigal Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Madrigal Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Madrigal Pharmaceuticals has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Madrigal Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Madrigal Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Madrigal Pharmaceuticals Company Filings, last reported 3 months ago.

DB:YDO1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 476.98 0.00 483.72
2018-09-30 482.91 0.00 488.54
2018-06-30 486.09 0.00 490.31
2018-03-31 177.18 0.00 182.83
2017-12-31 182.26 0.00 191.53
2017-09-30 54.31 0.00 62.14
2017-06-30 61.63 0.00 67.17
2017-03-31 34.45 0.00 40.13
2016-12-31 36.41 0.00 40.50
2016-09-30 37.59 0.00 39.56
2016-06-30 -42.28 45.97 4.10
2016-03-31 -50.63 50.82 0.62
2015-12-31 -48.91 49.10 0.31
2014-12-31 -42.07 42.19 0.15
  • Madrigal Pharmaceuticals has no debt.
  • Madrigal Pharmaceuticals currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Madrigal Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
  • Madrigal Pharmaceuticals has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 45.6% each year.
X
Financial health checks
We assess Madrigal Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Madrigal Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Madrigal Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Madrigal Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Madrigal Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Madrigal Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Madrigal Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:YDO1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:YDO1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 3.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Madrigal Pharmaceuticals has not reported any payouts.
  • Unable to verify if Madrigal Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Madrigal Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Madrigal Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Madrigal Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Madrigal Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Madrigal Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Madrigal Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Madrigal Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paul Friedman
COMPENSATION $1,364,982
AGE 75
TENURE AS CEO 2.8 years
CEO Bio

Dr. Paul A. Friedman, M.D., has been Chairman and Chief Executive Officer of Madrigal Pharmaceuticals, Inc. since July 22, 2016 and served as its President since July 22, 2016. Dr. Friedman is Co-Owner of SQN, LLC. He serves as a Partner of Vilicus Ventures, LLC. Dr. Friedman is a Cardiologist and Professor at Mayo Clinic. He is a Professor of Medicine and a consultant of cardiovascular electrophysiology. He has more than 20 years of experience in the pharmaceutical industry. He served as an Executive Chairman of Cerulean Pharma Inc. since October 29, 2014 until June 2016. He served as the Chief Executive Officer of Incyte Corporation from November 2001 to January 13, 2014 and served as its President from May 2004 to January 13, 2014. where he led a transformation of the business from genomics to a therapeutic focus establishing its foundation as a leader in oncology. From 1998 to October 2001, Dr. Friedman served as the President of DuPont Pharmaceuticals Research Laboratories. From 1994 to 1998, he served as the President of Research and Development of The DuPont Merck Pharmaceutical Company. From 1991 to 1994, he served as Senior Vice President at Merck Sharp & Dohme Research Laboratories. He held executive and R&D positions at Merck Research Laboratories. From 1985 to 1991, he held several executive positions at Merck. From 1974 to 1985, he served as an Associate Professor of Medicine and Pharmacology at Harvard Medical School. He has been Director at Alexion Pharmaceuticals, Inc. since September 14, 2017. He has been a Director of Cerulean Pharma Inc. since January 2014 until 2017 and Durata Therapeutics, Inc. since May 16, 2013 until 2014. He has been a Non Executive Director of Gliknik, Inc. since February 25, 2013. He has been an Independent Director of Navitor Pharmaceuticals, Inc. since June 2015. He has been a Director of Incyte Corporation since November 2001. He has been a Member of Clinical and Scientific Advisory Board of Verastem, Inc. since May 2017 and served as its Independent Director since May 2014 until April 27, 2017. Dr. Friedman served as a Director of Synta Pharmaceuticals Corp. since March 2014 until 2016. He served as a Director of Auxilium Pharmaceuticals Inc. from June 2010 to January 29, 2015. He served as a Director of Sirtris Pharmaceuticals, Inc. from March 2008 to June 2008. He served as a Director of Bausch & Lomb Incorporated from June 2004 to October 2007. He is a Diplomate of the American Board of Internal Medicine and a Member of the American Society of Clinical Investigation. He is the author of over 100 scientific publications. He has over 40 biomedical patents and has authored over 300 scientific publications, including books, book chapters and original articles. He is the reviewer or editor of over 15 influential medical journals and directs national and international medical education meetings. He has been the principal investigator of large, international, multicenter trials. He has also been the recipient of federal and regional research awards to assess and develop new healthcare technologies. He is the Vice Chair of Academic Affairs and Faculty Development at the Mayo Clinic. He is the Vice Chair of the Division of Cardiovascular Medicine at the Mayo Clinic. Dr. Friedman received an M.D. Degree from Harvard Medical School in 1969 and B.S. degree in Biology from Princeton University, Princeton, New Jersey, in 1964.

CEO Compensation
  • Paul's compensation has been consistent with company performance over the past year.
  • Paul's remuneration is about average for companies of similar size in Germany.
Management Team

Paul Friedman

TITLE
Chairman & CEO
COMPENSATION
$1M
AGE
75
TENURE
2.8 yrs

Becky Taub

TITLE
Founder
COMPENSATION
$1M
AGE
66

Marc Schneebaum

TITLE
Senior VP & CFO
COMPENSATION
$970K
AGE
64
TENURE
2.8 yrs

Tom Hare

TITLE
Senior Vice President of Clinical Management
Board of Directors Tenure

Average tenure and age of the Madrigal Pharmaceuticals board of directors in years:

2.8
Average Tenure
72
Average Age
  • The average tenure for the Madrigal Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Paul Friedman

TITLE
Chairman & CEO
COMPENSATION
$1M
AGE
75
TENURE
2.8 yrs

Becky Taub

TITLE
Founder
COMPENSATION
$1M
AGE
66
TENURE
7.6 yrs

Ken Bate

TITLE
Director
COMPENSATION
$232K
AGE
68
TENURE
2.8 yrs

Keith Gollust

TITLE
Director
COMPENSATION
$225K
AGE
72
TENURE
2.8 yrs

Rich Levy

TITLE
Director
COMPENSATION
$225K
AGE
60
TENURE
2.7 yrs

Fred Craves

TITLE
Lead Director
COMPENSATION
$220K
AGE
72
TENURE
2.8 yrs

Dave Milligan

TITLE
Director
COMPENSATION
$220K
AGE
77
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
24. Nov 18 Buy Paul Friedman Individual 20. Nov 18 20. Nov 18 4,000 €103.44 €413,759
19. Nov 18 Buy Paul Friedman Individual 19. Nov 18 19. Nov 18 4,000 €108.26 €433,058
19. Nov 18 Buy Frederick Craves Individual 19. Nov 18 19. Nov 18 2,000 €109.14 €217,740
13. Jun 18 Sell Marc Schneebaum Individual 11. Jun 18 11. Jun 18 -2,142 €243.45 €-521,470
13. Jun 18 Sell Bay City Capital LLC Company 11. Jun 18 11. Jun 18 -280,000 €243.45 €-68,165,965
13. Jun 18 Sell SQN, LLC Company 11. Jun 18 11. Jun 18 -73,526 €243.45 €-17,899,895
X
Management checks
We assess Madrigal Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Madrigal Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company’s lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.

Details
Name: Madrigal Pharmaceuticals, Inc.
YDO1
Exchange: DB
Founded: 2011
$1,447,106,555
15,417,064
Website: http://www.madrigalpharma.com
Address: Madrigal Pharmaceuticals, Inc.
Four Tower Bridge,
Suite 400,
West Conshohocken,
Pennsylvania, 19428,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM MDGL New Common Stock Nasdaq Capital Market US USD 25. Jul 2016
DB YDO1 New Common Stock Deutsche Boerse AG DE EUR 25. Jul 2016
LSE 0JXI New Common Stock London Stock Exchange GB USD 25. Jul 2016
Number of employees
Current staff
Staff numbers
17
Madrigal Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:54
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/10
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.